Evaluation of Field Sobriety Tests for Identifying Drivers Under the Influence of Cannabis: A Randomized Clinical Trial.


Journal

JAMA psychiatry
ISSN: 2168-6238
Titre abrégé: JAMA Psychiatry
Pays: United States
ID NLM: 101589550

Informations de publication

Date de publication:
01 09 2023
Historique:
medline: 7 9 2023
pubmed: 2 8 2023
entrez: 2 8 2023
Statut: ppublish

Résumé

With increasing medicinal and recreational cannabis legalization, there is a public health need for effective and unbiased evaluations for determining whether a driver is impaired due to Δ9-tetrahydrocannabinol (THC) exposure. Field sobriety tests (FSTs) are a key component of the gold standard law enforcement officer-based evaluations, yet controlled studies are inconclusive regarding their efficacy in detecting whether a person is under the influence of THC. To examine the classification accuracy of FSTs with respect to cannabis exposure and driving impairment (as determined via a driving simulation). This double-blind, placebo-controlled parallel randomized clinical trial was conducted from February 2017 to June 2019 at the Center for Medicinal Cannabis Research, University of California, San Diego. Participants were aged 21 to 55 years and had used cannabis in the past month. Data were analyzed from August 2021 to April 2023. Participants were randomized 1:1:1 to placebo (0.02% THC), 5.9% THC cannabis, or 13.4% THC cannabis smoked ad libitum. The primary end point was law enforcement officer determination of FST impairment at 4 time points after smoking. Additional measures included officer estimation as to whether participants were in the THC or placebo group as well as driving simulator data. Officers did not observe driving performance. The study included 184 participants (117 [63.6%] male; mean [SD] age, 30 [8.3] years) who had used cannabis a mean (SD) of 16.7 (9.8) days in the past 30 days; 121 received THC and 63, placebo. Officers classified 98 participants (81.0%) in the THC group and 31 (49.2%) in the placebo group as FST impaired (difference, 31.8 percentage points; 95% CI, 16.4-47.2 percentage points; P < .001) at 70 minutes after smoking. The THC group performed significantly worse than the placebo group on 8 of 27 individual FST components (29.6%) and all FST summary scores. However, the placebo group did not complete a median of 8 (IQR, 5-11) FST components as instructed. Of 128 participants classified as FST impaired, officers suspected 127 (99.2%) as having received THC. Driving simulator performance was significantly associated with results of select FSTs (eg, ≥2 clues on One Leg Stand was associated with impairment on the simulator: odds ratio, 3.09; 95% CI, 1.63-5.88; P < .001). This randomized clinical trial found that when administered by highly trained officers, FSTs differentiated between individuals receiving THC vs placebo and driving abilities were associated with results of some FSTs. However, the high rate at which the participants receiving placebo failed to adequately perform FSTs and the high frequency that poor FST performance was suspected to be due to THC-related impairment suggest that FSTs, absent other indicators, may be insufficient to denote THC-specific impairment in drivers. ClinicalTrials.gov Identifier: NCT02849587.

Identifiants

pubmed: 37531115
pii: 2807719
doi: 10.1001/jamapsychiatry.2023.2345
pmc: PMC10398547
doi:

Substances chimiques

Dronabinol 7J8897W37S
Hallucinogens 0
Cannabinoid Receptor Agonists 0

Banques de données

ClinicalTrials.gov
['NCT02849587']

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

914-923

Commentaires et corrections

Type : CommentIn

Auteurs

Thomas D Marcotte (TD)

Center for Medicinal Cannabis Research, Department of Psychiatry, University of California, San Diego.

Anya Umlauf (A)

Center for Medicinal Cannabis Research, Department of Psychiatry, University of California, San Diego.

David J Grelotti (DJ)

Center for Medicinal Cannabis Research, Department of Psychiatry, University of California, San Diego.

Emily G Sones (EG)

Center for Medicinal Cannabis Research, Department of Psychiatry, University of California, San Diego.

Kyle F Mastropietro (KF)

Joint Doctoral Program in Clinical Psychology, San Diego State University/University of California, San Diego.

Raymond T Suhandynata (RT)

Center for Medicinal Cannabis Research, Department of Pathology, University of California, San Diego.
Center for Medicinal Cannabis Research, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego.

Marilyn A Huestis (MA)

Institute for Emerging Health Professions, Thomas Jefferson University, Philadelphia, Pennsylvania.

Igor Grant (I)

Center for Medicinal Cannabis Research, Department of Psychiatry, University of California, San Diego.

Robert L Fitzgerald (RL)

Center for Medicinal Cannabis Research, Department of Pathology, University of California, San Diego.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH